Shares of Pfizer Inc. (NYSE:PFE) ended Thursday session in red amid volatile trading. The shares closed down -0.12 points or -0.34% at $34.68 with 15.92 million shares getting traded. Post opening the session at $34.73, the shares hit an intraday low of $34.61 and an intraday high of $34.94 and the price vacillated in this range throughout the day. The company has a market cap of $209.87 billion and the numbers of outstanding shares have been calculated to be 6.07 billion shares.
Pfizer Inc. (PFE) invites investors and the general public to listen to a webcast of a discussion with Ian Read, Chairman and Chief Executive Officer, at the 2016 Wells Fargo Healthcare Conference on Thursday, September 8, 2016 at 12:15 p.m. Eastern Daylight Time.
To listen to the webcast, visit our web site at www.pfizer.com and click on the “2016 Wells Fargo Healthcare Conference” link in the For Investors section located on the lower right-hand corner of that page. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com beginning now.
Visitors will be able to listen to an archived copy of the webcast at www.pfizer.com.
Shares of Apricus Biosciences Inc (NASDAQ:APRI) ended Thursday session in red amid volatile trading. The shares closed down -0.009 points or -2.62% at $0.342 with 432,737.00 shares getting traded. Post opening the session at $0.35, the shares hit an intraday low of $0.34 and an intraday high of $0.35 and the price vacillated in this range throughout the day. The company has a market cap of $22.56 million and the numbers of outstanding shares have been calculated to be 66.35 million shares.
Apricus Biosciences Inc (APRI) on Aug. 15, 2016 announced that Ferring Pharmaceuticals, the Company`s new partner in the United Kingdom, has received the United Kingdom marketing authorization for Vitaros®.
“We are pleased that the transfer of the U.K. marketing authorization to Ferring has been completed and we look forward to the product`s continued growth in this major ED market,” said Richard Pascoe, Chief Executive Officer of Apricus. “This follows the previously announced transfer of the German marketing authorization, marking the second in a series of marketing authorization transfers to Ferring that we anticipate will occur later this quarter.”
Earlier this year, the Company expanded its exclusive Vitaros distribution agreement with Ferring International S.A. in Latin America to now include Germany, Austria, Belgium, Denmark, Finland, Iceland, Luxembourg, Norway, the Netherlands, Sweden, Switzerland and certain countries in Asia (previously Sandoz`s territories), the United Kingdom (previously Takeda`s territory) and Korea. Under the terms of the agreement, Apricus has received a total of $4.5 million in upfront payments from Ferring, in addition to a regulatory milestone payment of $1.6 million. Apricus is eligible to receive up to an additional $28 million in regulatory, launch and sales milestones, plus royalties on future net sales.